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Abstract
Background: Methamphetamine use is associated with HIV acquisition and transmission among men who have
sex with men (MSM). Contingency management (CM), providing positive reinforcement for drug abstinence and
withholding reinforcement when abstinence is not demonstrated, may facilitate reduced methamphetamine use
and sexual risk. We compared CM as a stand-alone intervention to a minimal intervention control to assess the
feasibility of conducting a larger, more definitive trial of CM; to define the frequency of behavioral outcomes to
power such a trial; and, to compute preliminary estimates of CM’s effectiveness.
Methods: We randomly assigned 127 MSM from Seattle, WA who use methamphetamine to receive a 12-week CM
intervention (n = 70) or referral to community resources (n = 57).
Results: Retention at 24 weeks was 84%. Comparing consecutive study visits, non-concordant UAI declined
significantly in both study arms. During the intervention, CM and control participants were comparably likely to
provide urine samples containing methamphetamine (adjusted relative risk [aRR] = 1.09; 95%CI: 0.71, 1.56) and to
report non-concordant UAI (aRR = 0.80; 95%CI: 0.47, 1.35). However, during post-intervention follow-up, CM
participants were somewhat more likely to provide urine samples containing methamphetamine than control
participants (aRR = 1.21; 95%CI: 0.95, 1.54, P = 0.11). Compared to control participants, CM participants were
significantly more likely to report weekly or more frequent methamphetamine use and use of more than eight
quarters of methamphetamine during the intervention and post-intervention periods.
Conclusions: While it is possible to enroll and retain MSM who use methamphetamine in a trial of CM conducted
outside drug treatment, our data suggest that CM is not likely to have a large, sustained effect on
methamphetamine use.
Trial Registration: ClinicalTrials.gov Identifier NCT01174654
Background
Men who have sex with men (MSM) who report using
methamphetamine are 1.5 to 2.9 times more likely to
acquire HIV than men who do not [1-6]. MSM describe
sex on methamphetamine as “automatic” and “compul-
sive” [7,8], and methamphetamine use has been
consistently associated with sexual behaviors and biolo-
gical factors that may facilitate HIV acquisition and
transmission [9].
Reductions in sexual risk accompany participation in
substance abuse treatment and peer-support programs
[10,11]. In particular, contingency management (CM)
has emerged as a promising intervention to reduce
methamphetamine use and HIV-related sexual risk
among MSM. CM is the practice of providing incentives
for meeting a specified behavioral goal (e.g., abstinence
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the goal is not met. Scientists have used CM to success-
fully promote an array of behavioral goals in diverse
populations [12-14]. In a randomized trial that enrolled
MSM seeking outpatient drug treatment, CM and cogni-
tive behavioral therapies resulted in similar reductions in
methamphetamine use and sexual risk [15]. The results
of that trial, as well as data indicating high levels of
interest in CM [16], prompted the San Francisco
Department of Public Health to implement the Positive
Reinforcement Opportunities Project (PROP), a stand-
alone CM intervention among non-treatment-seeking
MSM [17,18].
Despite evidence supporting the potential effectiveness
of CM, the intervention’s effects on methamphetamine
use and sexual risk have not been tested using a mini-
mal intervention control. We conducted a randomized
controlled trial of CM to reduce methamphetamine use
and sexual risk among MSM outside of drug treatment.
The goals of the study were to assess the feasibility of
conducting a larger, more definitive trial of CM; to
define the frequency of behavioral outcomes to power
such a trial; and, to compute preliminary estimates of
CM’s effectiveness.
Methods
Study population
We enrolled MSM from Seattle, WA. Between June
2007 and August 2008, participants were recruited
through referrals from an STI clinic; an HIV clinic;
community-based organizations (CBOs); printed media;
radio; community outreach; and, referral by peers parti-
cipating in the study.
This study was initially designed to inform the design
of a trial to test whether CM could prevent HIV acquisi-
tion among HIV-negative men who use methampheta-
mine. Therefore, from June 2007 to November 2007, we
enrolled only HIV-negative men. Because of slow enroll-
ment of HIV-negative men, in November 2007, we
opened the study to HIV-positive men and revised the
study objective to test whether a CM intervention could
reduce HIV acquisition and transmission risk. Several
studies illustrate that a considerable proportion of HIV-
positive men use methamphetamine and that metham-
phetamine facilitates HIV transmission behaviors [9].
Additional inclusion criteria were: age ≥18 years; willing-
ness to be randomized and provide locator information;
and, no plans to move from the study catchment area
within 6 months of enrollment. Behavioral eligibility cri-
teria were ≥1e p i s o d e so fa n a ls e xa n d≥2e p i s o d e so f
methamphetamine use in the month prior to screening.
We did not require a methamphetamine-positive urine
sample for enrollment as we thought this requirement
would limit the utility of CM as a public health
intervention in practice. We excluded participants who
reported a mutually monogamous relationship with a
partner of the same HIV status lasting ≥2 years and
men who expressly asked for detoxification, counseling,
or drug rehabilitation services. HIV status was the only
eligibility criterion modified during the course of the
study.
Study intervention and design
The study intervention was a 12-week CM program,
adapted from previous studies, in which vouchers of
escalating value were offered for consecutive urine sam-
ples that did not contain methamphetamine or crack or
cocaine (herein referred to as cocaine) metabolites [15].
Initially, the intervention consisted of thrice-weekly
drop-in urine testing visits for a total of 36 visits. Vou-
chers started at $2.50 for the first stimulant-free sample
and increased by $1.25 for every consecutive stimulant-
free sample thereafter up to a maximum of $10.00. Par-
ticipants submitting three stimulant-free urine samples
in a row earned a $10.00 bonus. The maximum payout
for this program was $453.75, similar to the payout in
other programs [17,18]. When participants submitted a
stimulant-containing sample, or missed a visit, no vou-
chers were issued and the value of the voucher for the
subsequent stimulant-free sample was reset to $2.50. If
a participant submitted a week of stimulant-free samples
after submitting a sample containing stimulant metabo-
lites, he returned to the voucher value prior to the sti-
mulant-containing sample ("rapid reset”) [19]. Vouchers
were redeemable immediately upon accrual for pre-paid
gift cards and goods and services; we never offered cash.
All CM participants signed a contract delineating the
expectations of the CM program [20]. Study personnel
administering the CM intervention followed a simple,
scripted protocol for the reporting of results of urine
testing and administering vouchers. Such a protocol was
used to avoid the provision of counseling around the
results of the urine testing. The protocol, which
required no formal training, was developed by one of us
(SS) who has extensive expertise in delivering CM
interventions.
All seven participants enrolled in the study while the
above procedures were in place reported difficulty
adhering to the intervention schedule, and only two
attended ≥12 of their 36 visits. In response, in Septem-
ber 2007, we reduced the number of weekly urine test-
ing visits to two (24 visits over the 12-week
intervention) and increased the value of vouchers for
the first stimulant-free urine sample to $7.50; other stu-
dies have employed a similar schedule [21]. As before,
these vouchers increased by $1.25 for each consecutive
stimulant-free sample to a maximum of $10.00. Addi-
tionally, we gave participants a $20.00 bonus for two
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out for this program was $476.25. We continued to
withhold vouchers and reset voucher values to baseline
for urines containing stimulants and for missed visits;
however, to encourage participants to attend visits, we
gave men submitting stimulant-positive samples a vou-
cher worth $2.50.
Under the initial CM intervention schedule, drop-in
urine-testing visits were available from 10:00 am to
6:00 pm on Tuesdays, Thursdays, and Saturdays; we
offered extended hours for working participants. After
the enrollment visit, we sent postcards or e-mails to all
participants encouraging participation in the interven-
tion. We reminded participants who did not attend
urine-testing visits for the first week by phone or e-mail.
We sent postcards, phoned, or e-mailed all CM partici-
pants again at the midpoint of the intervention period.
Under the revised CM intervention schedule, drop-in
urine testing visits were available from 10:00 am to
6:00 pm on Tuesdays and Saturdays with flexible hours
for working participants. Postcard, phone, and e-mail
reminder strategies remained the same.
We tested urine samples with the QuickScreen Pro
Multi-Drug Screening Test (Phamatech, Inc., San Diego,
CA), a point-of-care test used to qualitatively detect sti-
mulant metabolites. For this assay, the estimated mean
detection time in urine ranges from 43.6 to 66.9 hours
for methamphetamine [22] and is 88.4 hours for ben-
zoylecgonine, a cocaine metabolite [23]. We repeated
10% of all urine tests; none were discordant. Study staff
monitored the collection of all urine samples and tested
the samples immediately after their provision.
Participants randomized to both control and CM arms
received a printed list of local counseling, treatment,
and outreach services at baseline and at each study visit.
Study staff offered all participants assistance accessing
services. Control participants did not submit twice-
weekly urine samples and did not receive vouchers dur-
ing the first 12 weeks of the study.
The study randomized participants using block sizes
of two, four, and eight varied randomly with a pseudo-
random number generator, a deterministic process use
to generate an effectively unpredictable sequence of
numbers [24]. The randomization list was used to
assemble sequentially numbered, sealed, opaque envel-
opes containing intervention arm assignments. The
research coordinator and principal investigator were
blinded to the randomization code. From June 2007 to
April 2008, participants were randomized 1:1 to the
intervention and control arms under a protocol funded
by the National Institute on Drug Abuse. In April 2008,
we received additional funding from Public Health–Seat-
tle & King County (PHSKC) to deliver the CM interven-
tion, but not to enroll additional control participants.
Therefore, between April 2008 and August 2008, we
randomly assigned participants 3:1 to the intervention
and control arms. We conducted analyses with and
without the men enrolled under the 3:1 randomization
scheme. Results were similar and we present the results
of analyses that included all randomized men in this
manuscript. While uneven randomization schemes may
affect a trial’s statistical efficiency, they have no impact
on a trial’s validity [25]. Follow-up ended in February
2009.
The same study personnel administered the CM inter-
vention and conducted the study visits. These personnel
also performed data entry of the results of the urine
testing and HIV/STI testing. The behavioral endpoints
were automatically transferred from the ACASI to a
database without the potential for modification. It was
not possible to blind those administering the CM inter-
vention to a participant’s study arm.
The University of Washington institutional review
board approved the study protocol. All participants pro-
vided written informed consent.
Study procedures
All study procedures took place at a large, public-transport
accessible, community-based AIDS service organization.
We screened participants for eligibility by phone and in
person. All participants attended scheduled study visits
every six weeks for six months. At each study visit, partici-
pants completed an audio computer-assisted self-interview
(ACASI) that used a 6-week recall period and included
questions about sexual behavior and substance use at the
respondent- and partnership-level. Participants submitted
urine samples for methamphetamine and cocaine metabo-
lite testing at each of these visits.
At enrollment, 12 weeks, and 24 weeks, participants
were tested for HIV/STI after completing the ACASI
[26]. Participant-centered risk reduction counseling
accompanied all testing [27], and condoms and lubricant
were offered to all participants. Given the connections
between substance use and sexual risk, HIV risk reduc-
tion counseling often included discussions of substance
use.
Study endpoints
The primary outcome was report of unprotected anal
intercourse with a partner of unknown or discordant
HIV status (non-concordant UAI) in the prior six
weeks. The study included four secondary endpoints:
the number of non-concordant UAI partners; results of
methamphetamine urine testing; self-reported weekly or
more frequent use of methamphetamine; and, self-
reported use of >8 quarters (two grams) of methamphe-
tamine. We chose non-concordant UAI as the primary
outcome because this study was designed as a
Menza et al. BMC Public Health 2010, 10:774
http://www.biomedcentral.com/1471-2458/10/774
Page 3 of 13preliminary test of whether CM can be ultimately
employed as an HIV prevention tool. We have pre-
viously shown this metric to be associated with HIV
acquisition [28]. The secondary substance use outcomes
represent intermediate variables in the causal chain in
which methamphetamine use may facilitate the high risk
sex that in turn leads to HIV/STI transmission.
Reliability of behavioral study endpoints
We conducted a test-retest reliability study of the beha-
vioral endpoints assessed in this trial [29]. From Decem-
ber 2006 to March 2007, we enrolled 102 MSM
recruited from an STI clinic and an HIV clinic to com-
plete the ACASI employed in this study. Of the 102
men who completed an initial ACASI, 98 (96%)
returned to complete a second ACASI in a median of 4
days (range: 2-5). Participants took no more than 38
minutes to complete the initial ACASI. We calculated
reliabilities using kappa statistics for binary outcomes
and intraclass correlation coefficients by repeated mea-
sures analysis of variance (ANOVA) for continuous out-
comes. The reliabilities of self-reported non-concordant
UAI, weekly or more frequent use of methamphetamine,
number of non-concordant UAI partners, and number
of quarters of methamphetamine were 0.72 (95%CI:
0.47, 0.87), 0.88 (95%CI: 0.62, 0.99), 0.85 (95%CI: 0.78,
0.91), and 0.96 (95%CI: 0.94, 0.99), respectively.
Statistical analyses
The primary purpose of this trial was to gather data for
the design of a phase IIb or III clinical trial. The study
was originally designed to follow 60 individuals. Assum-
ing that 14% of participants would report non-concor-
dant UAI at baseline, this sample size was chosen to
provide estimates of the proportion of men who report
non-concordant UAI in the prior six weeks with an
expected width of the 95% confidence interval (CI) of
0.085. We expected to lose 25% of our study population
to follow-up and aimed to enroll 80 participants. Addi-
tional resources, however, allowed us to enroll 127
participants.
We used chi-squared tests and t-tests to compare
retention at the 24-week study visit and CM interven-
tion adherence, respectively, between groups of partici-
pants defined by selected characteristics. We used
generalized estimating equations (GEE) to estimate the
proportion of participants reporting non-concordant
UAI in the prior six weeks at each study visit. Analyses
estimating the effectiveness of CM were intention to
treat, on the basis of a binomial regression models with
log links, to calculate relative risks comparing the pro-
portion of men reporting non-concordant UAI between
the study groups at study visits during the 12-week
intervention and 12-week follow-up periods [30]. Our
analyses of secondary binary endpoints employed the
same analytic methods. Finally, we used a GEE model
with a log link and negative binomial errors to evaluate
the intervention’s effect, expressed as a rate ratio, on the
number of non-concordant UAI partners. We defined
statistical significance at the P < 0.05 level.
We pre-selected baseline covariates that we thought
would most strongly predict our outcomes of interest
for adjusted analyses, including predictors of retention
at the 24-week study visit. Of these covariates, we
adjusted for variables that resulted in at least a 10%
change in the adjusted RR (aRR) compared to the unad-
justed RR [31]. We chose such strict criteria because of
our relatively small sample size and because several
potential confounders differed between our intervention
and control groups. All analyses included a covariate
indicating the baseline value of the outcome of interest.
Estimates of the proportion of men reporting non-
concordantUAI at each visit and analyses comparing
any non-concordant UAI and number of non-concor-
dant UAI partners between CM and control were also
adjusted for HIV status and use of other substances
(inhaled nitrites, gamma-hydroxybutyrate, ecstasy, or
erectile dysfunction medications) in the prior 6 weeks at
baseline. Analysis of detection of methamphetamine use
by urinalysis was also adjusted for stage of change for
methamphetamine use at baseline. We note that dura-
tion of methamphetamine use and injection use of
methamphetamine were both evaluated as potential con-
founders; their inclusion in models that already included
the above variables produced similar results to analyses
without these two predictors.
We assessed participants’ stage of change for metham-
p h e t a m i n eu s eb yas i n g l eq u e s t i o n[ 3 2 , 3 3 ] :“Have you
been trying to cut back or stop using methampheta-
mine?” This question was added after the first 19 parti-
cipants were enrolled as it was not a variable we had
initially planned to collect. The pattern of missingness,
however, is missing completely at random (MCAR)
which is unlikely to introduce bias to complete case
analyses like the one presented in this manuscript [34].
Results
Enrollment, retention, and participant characteristics
Over our 15-month enrollment period, we screened 222
men for eligibility (14.8/month) and enrolled and rando-
mized 127 men (8.5/month). Of these randomized parti-
cipants, 107 (84%) attended the 24-week study visit;
retention at 6-week assessments was similar for both
groups (Figure 1). HIV-negative men were less likely to
attend the 24-week study visit than HIV-positive men
(74% v. 93%, P < 0.01) and men who reported metham-
phetamine use for ≥10 years were less likely to attend
the 24-week study visit than men who reported
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0.05).
The largest difference in follow-up between the CM
and control group was for the first visit after baseline
(69% v. 77%). Of the 22 CM participants loss-to-follow-
up at this visit, one was incarcerated, one was in a drug
rehabilitation program, three withdrew from the study,
and 17 could not be located for study visit attendance.
Among the 13 control group participants who did not
complete the first follow-up visit, one had died, two
withdrew from the study, and 10 could not be located
for study visit attendance.
Table 1 presents characteristics of the study popula-
tion. The only statistically significant difference between
the study populations at baseline was that between the
distributions of race/ethnicity (P = 0.03).
CM intervention adherence
Table 2 provides metrics of intervention adherence
among CM participants. Participants who earned <
$15,000 per year attended more visits than participants
who earned ≥$15,000 per year (41% v. 20%, P = 0.04).
Participants who reported using methamphetamine
weekly or daily at baseline attended fewer visits than
participants who reported less frequent use (31% v. 51%,
P = 0.02) and participants whose urine contained
methamphetamine at baseline attended fewer urine test-
ing visits than participants whose urine did not contain
methamphetamine (26% v. 43%, P = 0.02). Since the
mean detection time of the methamphetamine assay is
shorter than the interval between urine testing visits, the
proportion of metabolite-free urine samples provided by
CM participants during the intervention visits may be
over-estimated.
Sexual risk
At baseline, 6-weeks, 12-weeks, 18-weeks, and 24-weeks,
the adjusted probabilities of reporting non-concordant
UAI in the prior six weeks were 31.0% (95%CI: 27.6%,
34.3%), 19.7% (95%CI: 16.3%, 23.1%), 12.1% (95%CI:
9.9%, 14.4%), 9.1% (95%CI: 7.2%, 10.9%) and 10.2% (95%
CI: 8.3%, 12.1%), respectively. Figure 2 presents the
adjusted proportion of men reporting non-concordant
UAI at each study visit by study arm. Comparing partici-
pants at study visits six weeks apart, participants at the
later study visit were less likely to report non-concordant
UAI in both the CM (aRR = 0.80; 95%CI: 0.64, 0.99) and
control (aRR = 0.84; 95%CI: 0.71, 1.00) arms than partici-
pants at the earlier study visit.
CM and control participants were similarly likely to
report non-concordant UAI during the 12-week inter-
vention period. CM participants were less likely than
control participants to report non-concordant UAI dur-
ing the subsequent 12-week follow-up period, and also
reported fewer non-concordant UAI partners than con-
trol participants during both the intervention and fol-
low-up periods. None of these differences were
statistically significant (Table 3).
One man in CM arm and one man in the control arm
acquired pharyngeal gonoccocal infection (3.4 v. 4.5 per
100 person-years; P = 0.43). There were no incident
syphilis, rectal gonococcal, or rectal chlamydial infec-
tions. Among the HIV-negative participants, one man in
the CM arm and no men in the control arm acquired
HIV (8.9 v. 0 per 100 person-years; P = 0.27).
Stimulant use
During the 24 weeks of follow-up at the 6-week study
visits attended by both CM and control participants, 28
(49%) control participants and 44 (63%) CM participants
submitted ≥1 sample containing methamphetamine
metabolites; 26 (46%) control participants and 23 (33%)
CM participants submitted ≥1 sample containing
cocaine metabolites; and, 43 (75%) control participants
and 55 (79%) CM participants submitted ≥1s a m p l e
containing methamphetamine or cocaine metabolites.
CM and control participants were comparably likely to
submit urine samples positive for methamphetamine at
study visits during the intervention period (Table 4);
however, during the follow-up period, CM participants
were somewhat more likely to submit a urine sample
containing methamphetamine (P = 0.11).
222 assessed for eligibility
95 excluded
    81 did not meet behavioral eligibility
      3 planned to move within 6 months
    11 eligible but refused to participate
127 underwent baseline
assessment
70 assigned to contingency
management
57 assigned to control
Follow-up visits:
  6 weeks: 48/70 (69%)
12 weeks: 56/70 (80%)
18 weeks: 53/70 (76%)
24 weeks: 60/70 (86%)
Follow-up visits:
  6 weeks: 44/57 (77%)
12 weeks: 46/57 (81%)
18 weeks: 46/57 (81%)
24 weeks: 47/57 (82%)
70 included in analysis 57 included in analysis
127 randomized
Figure 1 Participant flow through the study.
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a
Total Sample
(n = 127)
Contingency
Management (n = 70)
Control
(n = 57)
Recruitment
Peer-referral 64 (50) 35 (50) 29 (51)
Healthcare provider, STD or HIV clinic 28 (22) 15 (21) 13 (24)
Self-referral via community advertising 21 (16) 13 (19) 8 (14)
Community-based organization 7 (5) 4 (6) 3 (5)
Other, unknown 7 (5) 3 (4) 4 (7)
Randomization
1:1 100 (79) 50 (71) 50 (88)
3:1 27 (21) 20 (29) 7 (12)
Demographics
Age (years, median [range]) 39 (18-60) 40 (18-60) 37 (19-57)
Race/Ethnicity
b
Black, African American 10 (8) 2 (3) 8 (14)
Hispanic, Latino 17 (13) 12 (17) 5 (9)
Native American, Alaska Native 8 (6) 4 (6) 4 (7)
White 76 (60) 47 (67) 29 (51)
Other race/ethnicity, multiracial, unknown 16 (13) 5 (7) 11 (19)
Education
Less than High School 19 (15) 10 (14) 9 (16)
High School 30 (24) 17 (24) 13 (23)
Some college, vocational/technical training 60 (47) 35 (50) 25 (45)
College or greater 13 (10) 6 (9) 7 (12)
Missing 5 (4) 2 (3) 2 (4)
Annual income less than $15,000 90 (71) 53 (76) 37 (65)
Homeless or marginally housed 27 (21) 17 (24) 10 (17)
Neither employed nor attending school 89 (70) 51 (73) 38 (67)
HIV status
Negative 57 (45) 30 (43) 27 (47)
Positive 70 (55) 40 (57) 30 (53)
Sexual orientation
Gay, homosexual 80 (63) 47 (67) 33 (58)
Bisexual 28 (22) 14 (20) 14 (25)
Straight, heterosexual 1 (1) 1 (1) 0
Queer, same gender loving, other 18 (14) 8 (11) 10 (17)
Sexual Behavior, prior 6 weeks
Number of sex partners (median [IQR]) 3 (2-8) 4 (2-10) 3 (2-6.5)
Number of anal sex partners (median [IQR]) 2 (1-5) 2 (1-6) 2 (1-5)
Number of nonconcordant UAI partners (median [range]) 0 (0-35) 0 (0-35) 0 (0-16)
Nonconcordant UAI 35 (28) 21 (30) 14 (25)
Use of methamphetamine with anal sex 102 (80) 59 (84) 43 (75)
Exchanged sex for methamphetamine 20 (16) 11 (16) 9 (16)
Methamphetamine Use
Duration of methamphetamine use, years (median [IQR]) 11 (5-19) 14 (6-19) 11 (5-16)
Weekly or daily methamphetamine use, prior 6 weeks 83 (65) 51 (73) 32 (56)
Used more than 8 quarters of methamphetamine, prior 6 weeks 59 (46) 37 (53) 22 (39)
Injection of methamphetamine, prior 6 weeks 69 (54) 41 (59) 28 (49)
Trans-theoretical stage of change: “Have you been trying to stop or cut down on
your methamphetamine use?”
“Yes, I have been trying for more than 6 months” (Maintenance) 49 (39) 25 (36) 24 (42)
“Yes, I have been trying for less than 6 months” (Action) 24 (19) 12 (17) 12 (21)
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control participants at the later study visit were less
likely to report either weekly or daily methamphetamine
use or using >8 quarters of methamphetamine in the
prior six weeks than participants at the earlier study
visit (aRR = 0.77; 95%CI: 0.68, 0.88 and aRR = 0.69;
95%CI: 0.56, 0.86, respectively); although the frequency
and quantity of methamphetamine use declined over
time among men in the CM arm, these changes were
not as large with respect to frequency (aRR = 0.89; 95%
C I :0 . 8 3 ,0 . 9 6 )a n dn o ts t a t i s t i c a l l ys i g n i f i c a n tw i t h
respect to quantity (aRR = 0.93; 95%CI: 0.85, 1.02). CM
participants were significant l ym o r el i k e l yt h a nc o n t r o l
participants to report weekly or daily methamphetamine
use and to report using >8 quarters of methampheta-
mine at each study visit; these differences were statisti-
cally significant during the 12-week follow-up period
(Table 4).
Accounting for baseline stage of change, control
group participants were more likely than CM partici-
pants to report being in the action or maintenance
stage of change for methamphetamine use during the
intervention (74% v. 63%, P = 0.57) and follow-up peri-
ods (81% v. 66%, P = 0.18); however, these differences
were not statistically significant. In the 6 weeks prior
to baseline, 19% of control participants and 14% of
CM participants participated in a substance abuse
treatment program or peer support group (P =0 . 4 5 ) .
After baseline, 26% of control participants and 21% of
CM participants reported participating in such inter-
ventions (P =0 . 3 8 ) .
Discussion
In this randomized controlled trial of CM, we enrolled
127 non-treatment-seeking MSM over 15 months and
successfully collected follow-up data on over 80% of
participants. These findings suggest that a randomized
controlled trial that specifically seeks to enroll this
population is acceptable and feasible. However, less than
half of our participants were HIV-negative and restrict-
ing enrollment to HIV-negative MSM who use metham-
phetamine, the population of interest for a trial using
HIV as an outcome, would be challenging. Unlike HIV-
negative men, HIV-positive men are often enrolled in
ongoing medical care and case management. HIV-posi-
tive men may also be more likely to recognize their
methamphetamine use as problematic with some
attributing their HIV infection to their methampheta-
mine use [35]. In addition, the success of peer recruit-
ment (over 50% of HIV-negative participants were
recruited through peers) over place-based recruitment
strategies that have been successful in other HIV pre-
vention trials [36] indicates that HIV-negative MSM
who use methamphetamine may not share the same
social and geographic spaces as HIV-negative men who
do not use methamphetamine. HIV-negative men may
have also been uncomfortable participating in a trial
conducted at an organization well known for its services
for HIV-positive individuals.
Unfortunately, our findings related to CM are dis-
couraging. First, a relatively small proportion of men
consistently provided urine specimens for the interven-
tion meaning that actual exposure to the intervention
Table 1 Characteristics of the study population at baseline
a (Continued)
“No, but I really want to start this month” (Preparation) 14 (11) 11 (16) 3 (5)
“No, but I really would like to try in the next 6 months” (Contemplation) 14 (11) 9 (13) 5 (9)
“No, and I am really not interested in trying” (Pre-contemplation) 6 (5) 3 (4) 3 (5)
Missing 20 (16) 10 (14) 10 (17)
Ever been in substance abuse treatment for methamphetamine use 32 (25) 17 (24) 15 (26)
Ever attended a support group for methamphetamine use 52 (41) 25 (36) 27 (47)
Other substance use, prior 6 weeks
Cocaine 35 (28) 17 (24) 18 (32)
Crack 53 (42) 26 (37) 27 (47)
Inhaled nitrites 59 (46) 35 (50) 24 (42)
Erectile dysfunction medications 39 (31) 26 (37) 13 (23)
Ecstasy 19 (15) 8 (11) 11 (19)
Gamma-hydroxybutyrate 25 (20) 16 (23) 9 (16)
Urine testing results
Urine positive for methamphetamine 44 (35) 28 (40) 16 (28)
Urine positive for cocaine metabolites 31 (24) 12 (17) 19 (33)
Urine positive for methamphetamine or cocaine metabolites 65 (51) 35 (50) 30 (53)
IQR, interquartile range; UAI, unprotected anal intercourse.
aData are n (%) unless otherwise noted.
b P < 0.05
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Page 7 of 13among men assigned to CM was quite limited. Several
factors may contribute to CM participants receiving
such a low “dose” of the intervention, including the
location, the magnitude of the incentives, time limita-
tions, and monitored collection of urine samples. Anec-
dotally, many men reported not attending urine-testing
visits because they knew their urine would test positive.
This anecdotal evidence is supported by our data. Out
of all of the CM visits attended, a median of 85% of
urine samples were free of stimulant metabolites. Sec-
ond, and most importantly, our findings suggest that
CM is very unlikely to be effective as a stand-alone
intervention among MSM. While the 95% CI around
the intervention-period aRR was very wide and does not
rule out the possibility that CM could reduce metham-
phetamine use during the period of actual intervention,
our follow-up period aRR and 95% CI exclude the possi-
bility that CM would have a large, sustained benefit on
methamphetamine use as a stand-alone intervention in
a population like the one we studied. In addition, the
control group reported larger declines in self-reported
use over study follow-up than the CM arm. Although
measures of sexual risk among our CM participants
were similar to or lower than those among control par-
ticipants, it is unclear how CM might result in lower or
similar levels of sexual risk if it increases methampheta-
mine use.
We are aware of six studies evaluating CM among indi-
viduals who use methamphetamine in outpatient sub-
stance abuse treatment [15,21,37-40]. Five of those trials
found that, compared to other psychosocial interventions,
CM leads to the submission of more stimulant-free urine
samples and an increased duration of abstinence from sti-
mulants during the CM intervention period [41]. None of
the three studies that followed participants beyond the
intervention period reported differential effects of CM
compared to other treatments, but all three studies
showed that all participants experienced sustained reduc-
tions in methamphetamine use for up to 8 months after
ceasing to receive CM. Among MSM seeking outpatient
substance abuse treatment, CM has been shown to be
comparable in decreasing methamphetamine use and
Table 2 Contingency management intervention metrics
Metric
a Participants (n = 70)
b
% Visits attended, mean (SD); median (IQR) 37 (1.4); 25 (8-54)
% Visits attended, n (%)
0% 4 (6)
1-25% 32 (46)
26-50% 15 (21)
51-75% 10 (14)
75-99% 6 (9)
100% 3 (4)
% Metabolite-free urine samples out of those attended, mean (SD); median (IQR) 75 (3.6); 85 (0.5-1.0)
% Metabolite-free urine samples out of total possible visits, mean (SD); median (IQR)
b 29 (1.3); 18 (8-42)
% Metabolite-free urine samples, n (%)
c
0% 7 (10)
1-25% 37 (53)
26-50% 13 (19)
51-75% 5 (7)
75-99% 6 (9)
100% 2 (3)
Number of continuous metabolite-free samples, mean (SD); median (IQR)
c 4.2 (5.5); 2 (1-5)
Number of continuous metabolite-free samples, n (%)
c
Never submitted a metabolite-free sample 7 (10)
Submitted only single, non-consecutive metabolite-free samples 25 (36)
2-8 28 (40)
9-12 4 (6)
13-24 6 (9)
Earnings, US$ mean (SD); median (IQR) 112 (138); 50 (15-150)
IQR, interquartile range; SD, standard deviation.
aData are n (%) unless otherwise noted.
b63 participants had 24 possible visits, 5 participants had 36 possible visits, 1 participant had 33 possible visits, and 1 participant had 25 possible visits (mean =
25 visits).
cWe assumed that during visits the participant did not attend, he would have submitted a urine sample positive for methamphetamine or cocaine metabolites.
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Figure 2 Adjusted proportion of participants reporting non-concordant UAI in the prior six weeks, by study arm.
Table 3 Effect of a contingency management intervention on reports of any non-concordant unprotected anal
intercourse in the prior 6 weeks and the number of non-concordant unprotected anal intercourse partners in the prior
6 weeks
Proportion reporting any non-concordant UAI, n (%)
Visit Total Contingency Management Control Unadjusted RR (95% CI) Adjusted RR
a (95% CI)
Baseline 35/127 (28) 21/70 (30) 14/57 (25)
Week 6 18/92 (20) 9/48 (19) 9/44 (20)
Week 12 12/102 (12) 8/56 (14) 4/46 (9) 1.13 (0.54, 2.37) 0.80 (0.47, 1.35)
Week 18 9/99 (9) 3/53 (6) 6/46 (13)
Week 24 11/107 (10) 6/60 (10) 5/47 (11) 0.67 (0.24, 1.85) 0.51 (0.21, 1.25)
Self-reported non-concordant UAI partners, mean (SD)
Visit Total Contingency Management Control Unadjusted Rate Ratio (95% CI) Adjusted Rate Ratio
b (95% CI)
Baseline 1.35 (4.6) 1.70 (5.5) 0.90 (2.7)
Week 6 0.47 (1.5) 0.35 (0.9) 0.60 (1.9)
Week 12 0.19 (1.0) 0.09 (0.3) 0.30 (1.4) 0.46 (0.14, 1.52) 0.58 (0.17, 1.90)
Week 18 0.12 (0.4) 0.09 (0.4) 0.15 (0.4)
Week 24 0.11 (0.4) 0.10 (0.3) 0.13 (0.4) 0.70 (0.25, 1.95) 0.49 (0.18, 1.37)
CI, confidence interval; RR, relative risk; SD, standard deviation; UAI, unprotected anal intercourse.
aAdjusted for HIV status, report of non-concordant UAI in the prior 6 weeks at baseline and use of other substances (inhaled nitrites, gamma-hydroxybutyrate,
ecstasy, or erectile dysfunction medications) in the prior 6 weeks at baseline.
bAdjusted for HIV status, number non-concordant UAI partners in the prior 6 weeks at baseline and use of other substances (inhaled nitrites, gamma-
hydroxybutyrate, ecstasy, or erectile dysfunction medications) in the prior 6 weeks at baseline.
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Page 9 of 13receptive UAI as other psychosocial interventions [15].
However, none of the previously published randomized
trials included a no-treatment/minimal intervention con-
trol arm making it difficult to determine whether the
absence of differences between CM and other interven-
tions reflects comparable levels of efficacy or an absence
of effect with all interventions.
Our study differs in four important ways from pre-
vious studies of CM. First, while we did not exclude par-
ticipants who were receiving other substance use
interventions, participants were not enrolled because
they were seeking drug treatment. Second, we compared
CM to a minimal intervention control arm. Third, CM
was employed as a stand-alone intervention. Finally, CM
participants were only expected to submit urines sam-
ples two times per week rather than three times, as has
been done in some, but not all studies of CM [21]. We
cannot say whether CM’s failure to reduce methamphe-
tamine use in our study reflects a lack of effect among
persons who are not expressly seeking drug treatment,
CM’s ineffectiveness as a stand-alone intervention, the
ineffectiveness of our CM schedule, or a more general
lack of efficacy of CM that would have been consistently
observed in other trials had those studies included no-
treatment/minimal intervention control groups.
We found that self-reported methamphetamine use
declined among control participants but remained rela-
tively stable among CM participants. We cannot readily
explain this effect. We do not believe that CM partici-
pants used vouchers to obtain methamphetamine, since
the difference in drug use by study arm was only evident
after CM recipients ceased to receive vouchers. Likewise,
we do not believe our findings simply reflect more accu-
rate reporting of methamphetamine use by CM partici-
pants since we found that CM recipients were also more
likely to test positive for methamphetamine. Participants
in the two study arms reported similar use of outside
treatment and support services, making it unlikely that
differential use of other treatments affected our results.
It is possible that participation in the CM arm may have
put participants in contact with other participants and
CBO clients in ways that facilitated access to and use of
methamphetamine. Similar phenomena have been
reported in other studies [42,43]. Also, discontinuation
of twice-weekly CM visits, which may have provided a
source of support for CM participants, may have led to
heavier methamphetamine use among CM participants
compared to controls.
Similar to a study of CM and other psychosocial inter-
ventions in the substance abuse treatment setting [15],
Table 4 Effect of a contingency management intervention on detection of methamphetamine use by rapid urine
screen and on self-reported frequency and quantity of methamphetamine use in the prior 6 weeks
Positive methamphetamine urinalysis, n (%)
Visit Total Contingency Management Control Unadjusted RR (95% CI) Adjusted RR
a (95% CI)
Baseline 44/127 (35) 28/70 (40) 16/57 (28)
Week 6 27/92 (29) 17/48 (35) 10/44 (23)
Week 12 33/100 (33) 20/55 (36) 13/45 (29) 1.39 (0.81, 2.38) 1.09 (0.76, 1.57)
Week 18 39/97 (40) 24/52 (46) 15/45 (33)
Week 24 39/105 (37) 29/58 (50) 10/47 (21) 1.77 (1.13, 2.78) 1.21 (0.95, 1.54)
Self-reported weekly or more frequent methamphetamine use, n (%)
Visit Total Contingency Management Control Unadjusted RR (95% CI) Adjusted RR
b (95% CI)
Baseline 83/127 (65) 51/70 (73) 32/57 (56)
Week 6 32/92 (35) 20/48 (42) 12/44 (27)
Week 12 39/102 (38) 25/56 (45) 14/46 (30) 1.50 (0.93, 2.42) 1.29 (0.82, 2.04)
Week 18 37/99 (37) 26/53 (49) 11/46 (24)
Week 24 40/107 (37) 29/60 (48) 11/47 (23) 2.06 (1.29, 3.29) 1.76 (1.13, 2.73)
Self-reported use of more than eight quarters of methamphetamine, n (%)
Visit Total Contingency Management Control Unadjusted RR (95% CI) Adjusted RR
c (95% CI)
Baseline 59/127 (46) 37/70 (53) 22/57 (39)
Week 6 22/91 (24) 14/47 (29) 8/44 (18)
Week 12 28/99 (28) 21/55 (37) 7/44 (16) 2.01 (1.09, 3.73) 1.80 (0.95, 3.40)
Week 18 23/97 (24) 19/52 (36) 4/45 (9)
Week 24 30/105 (29) 24/59 (40) 6/46 (13) 3.52 (1.70, 7.30) 3.02 (1.47, 6.23)
CI, confidence interval; RR, relative risk; one quarter of methamphetamine is equivalent to 0.25 grams. Statistically significant results (P < 0.05) are bolded.
aAdjusted for methamphetamine urinalysis result at baseline and stage of change for methamphetamine use at baseline (maintenance, action, preparation,
contemplation, pre-contemplation, missing).
bAdjusted for baseline self-reported weekly or more frequent use of methamphetamine in the prior 6 weeks.
cAdjusted for baseline self-reported use of more than eight quarters of methamphetamine in the prior 6 weeks.
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Page 10 of 13we found that sexual risk declined in both of our study
arms. However, in the case of the current study, our
comparison arm was a minimal intervention control
group. People who volunteer for studies may be more
motivated to change their behavior than those who do
not, participants may enroll during a period of high-risk
activity and decrease their risk independent of interven-
tion effects, and simply measuring a behavior may
change a participant’s behavior or reports of that beha-
vior [44]. Each of these explanations may contribute to
why sexual risk in our study, as in past studies, declined
in both control and CM arms. Had we not used a mini-
mal intervention control group and only measured parti-
cipants in the CM intervention, we might have
erroneously concluded that CM reduced sexual risk.
This finding emphasizes that no-treatment/minimal
intervention control groups are essential to rigorous
intervention evaluation.
We note that the characteristics of our study popula-
tion and the outcomes among CM participants were
generally similar to those in a San Francisco public
health program designed to reduce methamphetamine
use among MSM (PROP) from December 2003 to
December 2005. Our screening (14.8/month in the cur-
rent study and 10.3/month in PROP) and enrollment
rates (8.4/month and 7.4/month), attendance at CM vis-
its (37% and 41%), and incentives earned (24% and 31%
of the total possible) were similar [17]. Compared to
PROP participants [18], participants in the present study
were more likely to have used methamphetamine for
>10 years (50% v. 38%), but were less likely to report
weekly or more frequent methamphetamine use (64% v.
86%) and to be HIV-positive (55% v. 78%). More than
80% of men in both populations reported methampheta-
mine use with sex and 54% of participants reported
injecting methamphetamine at enrollment. These simila-
rities demonstrate that our trial probably closely repli-
cated what might occur in a non-research setting.
Our study has several important limitations. First, we
did not power the current study to detect differences
between study groups based on methamphetamine use
or sexual risk. Instead, this study was powered to pro-
vide precise estimates of the proportion of methamphe-
tamine-using MSM who report non-concordant UAI.
Despite this limitation, the precision of our post-
intervention period aRR rules out the potential of CM
to effect a large, sustained reduction in methampheta-
mine use as a stand-alone intervention, at least in the
population we followed. Second, randomization did not
provide us with study arms balanced with respect sev-
eral pertinent variables. In particular, persons assigned
to the CM arm were more likely to use methampheta-
mine at baseline, and higher levels of drug use have
been associated with inferior responses to CM in prior
studies [45]. It is possible that our results are subject to
confounding bias stemming from imbalances in vari-
ables that we did not measure. Third, we altered the
CM intervention after beginning the study. These modi-
fications may have not provided sufficient incentive for
abstinence from methamphetamine use [20]. Finally, our
measures of self-reported sexual behavior and substance
use are subject to social desirability bias.
Conclusions
In summary, our small, randomized trial found that a
12-week CM intervention was associated with a poten-
tial increase in methamphetamine use, but decreases in
sexual risk that were not statistically significant. While
our experience suggests that a larger, more definitive
controlled trial of CM to decrease methamphetamine
use and sexual risk may be feasible, our findings suggest
that CM would be unlikely to effect large, sustained
reductions in methamphetamine use among MSM.
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